154 related articles for article (PubMed ID: 37290787)
1. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
Siebenhaar F; Altrichter S; Bonnekoh H; Hawro T; Hawro M; Michaelis EG; Kantor AM; Chang AT; Youngblood BA; Singh B; Rasmussen HS; Maurer M
Br J Dermatol; 2023 Oct; 189(5):511-519. PubMed ID: 37290787
[TBL] [Abstract][Full Text] [Related]
2. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
3. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium.
Pyatilova P; Akin C; Alvarez-Twose I; Arock M; Bonadonna P; Brockow K; Butterfield JH; Broesby-Olsen S; Carter MC; Castells M; George TI; Gotlib J; Greiner G; Gülen T; Hartmann K; Hermine O; Horny HP; Jawhar M; Lange M; Lyons JJ; Maurer M; Metcalfe DD; Nedoszytko B; Niedoszytko M; Orfao A; Reiter A; Schwaab J; Sotlar K; Sperr WR; Triggiani M; Valent P; Siebenhaar F
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2015-2024. PubMed ID: 35724950
[TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Padilla B; Shields AL; Taylor F; Li X; Mcdonald J; Green T; Boral AL; Lin HM; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2021 Oct; 16(1):434. PubMed ID: 34663404
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.
Siebenhaar F; von Tschirnhaus E; Hartmann K; Rabenhorst A; Staubach P; Peveling-Oberhag A; Wagner N; Martus P; Carter MC; Metcalfe DD; Church MK; Maurer M; Weller K
Allergy; 2016 Jun; 71(6):869-77. PubMed ID: 26797792
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Akin C; Arock M; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
[TBL] [Abstract][Full Text] [Related]
7. Lirentelimab for severe and chronic forms of allergic conjunctivitis.
Anesi SD; Tauber J; Nguyen QD; Chang P; Berdy GJ; Lin CC; Chu DS; Levine HT; Fernandez AD; Roy N; Asbell PA; Kantor AM; Chang AT; Singh B; Youngblood BA; Jeng BH; Jhanji V; Rasmussen HS; Foster CS
J Allergy Clin Immunol; 2022 Sep; 150(3):631-639. PubMed ID: 35390403
[TBL] [Abstract][Full Text] [Related]
8. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
10. The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity.
Pyatilova P; Ashry T; Luo Y; He J; Bonnekoh H; Jiao Q; Moñino-Romero S; Hu M; Scheffel J; Frischbutter S; Hermans MAW; Youngblood BA; Maurer M; Siebenhaar F; Kolkhir P
Front Immunol; 2022; 13():930945. PubMed ID: 35958589
[TBL] [Abstract][Full Text] [Related]
11. Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.
Sabato V; Beyens M; Toscano A; Van Gasse A; Ebo DG
Curr Allergy Asthma Rep; 2024 Feb; 24(2):63-71. PubMed ID: 38217824
[TBL] [Abstract][Full Text] [Related]
12. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF
Shields AL; Taylor F; Lamoureux RE; Padilla B; Severson K; Green T; Boral AL; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2023 Mar; 18(1):69. PubMed ID: 36964624
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.
Matito A; Álvarez-Twose I; Morgado JM; Sánchez-Muñoz L; Orfao A; Escribano L
Int Arch Allergy Immunol; 2011; 156(1):104-11. PubMed ID: 21447966
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
16. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
17. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
18. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Taylor F; Akin C; Lamoureux RE; Padilla B; Green T; Boral AL; Mazar I; Mar B; Shields AL; Siebenhaar F
Orphanet J Rare Dis; 2021 Oct; 16(1):414. PubMed ID: 34627355
[TBL] [Abstract][Full Text] [Related]
19. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).
Horny HP; Sotlar K; Stellmacher F; Valent P; Grabbe J
J Clin Pathol; 2006 Mar; 59(3):264-8. PubMed ID: 16505276
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
